A Randomized Double-blind Placebo controlled Multi-center 2-part Phase 2 Study to Evaluate Efficacy Safety and Tolerability of RGH-706 in Prader-Willi Syndrome

Brief description of study

A Randomized, Double-blind Placebo controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome


Clinical Study Identifier: s22-00255
ClinicalTrials.gov Identifier: NCT05322096


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.